Leveraging Optimized Transient Expression For Material Generation And Early Stage Insight

By Jeonghwan Bae, Hyerim Park, Yingji Jin, and Janet Lee, Samsung Biologics

Determining developability and accelerating feasibility studies can greatly improve a drug's chances of moving through development. By using an optimized transient transfection platform, drug developers can accelerate their characterization and early development activities, facilitating continuity for a drug's scale-up. S-CHOsient, a novel transient expression platform from Samsung Biologics, is designed to expedite protein production for early development stages.

Key benefits of S-CHOsient include:

Faster Protein Production: S-CHOsient delivers high-quality protein within weeks, ideal for rapid material generation.

Enhanced Early Drug Discovery: Enables evaluation of multiple drug candidates at an early stage, facilitating faster selection of promising candidates.

Seamless Transition to Stable Cell Line Development: S-CHOsient uses the same CHO cell line as Samsung Biologics' S-CHOice platform for stable production, ensuring material consistency throughout development.

Preliminary Data Generation: S-CHOsient facilitates optimization of transfection conditions for complex molecules before stable cell line generation.

The platform has demonstrated the ability to produce high-quality materials across various protein formats, including monoclonal antibodies, Fc-fusion proteins, and bispecific antibodies. S-CHOsient ensures product quality consistency between transiently expressed proteins and those produced using stable cell lines derived from S-CHOice. Additionally, the platform exhibits successful scale-up capabilities, maintaining product quality attributes when transitioning from small-scale to large-scale cultures.

In conclusion, S-CHOsient offers a valuable tool for accelerating drug discovery by facilitating rapid protein production, streamlining early development processes, and ensuring material quality consistency throughout the development journey. When combined with Samsung Biologics' DEVELOPICK platform for developability assessment, S-CHOsient provides a comprehensive solution for reducing risks in early drug development and maximizing a therapy's potential for success.